Method for screening prophylactic or therapeutic agents for diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5

1. A therapeutic method for a respiratory disease or a pulmonary disease, comprising the steps of:

administering a substance for decreasing expression of MEX3B gene to a patient with a respiratory disease or a pulmonary disease, wherein the substance for decreasing of the MEX3B gene is

an antisense oligonucleotide which has a sequence complementary to an oligonucleotide comprising at least 10 contiguous nucleotides contained in the MEX3B gene or in an expression control region of the gene;

a double-stranded RNA containing at least 20 contiguous nucleotides in a coding region or an untranslated region in the sequence of an RNA to be transcribed from the sequence of the MEX3B gene, or a DNA encoding the double-stranded RNA; or

an artificial nuclease that is CRISPR/Cas nuclease,

wherein the CRISPR/Cas nuclease comprises a guide RNA having a sequence complementary to a partial sequence of 15 to 25 bases of the MEX3B gene and Cas nuclease;

wherein the MEX3B gene is a gene consisting of the sequence described in SEQ ID NO: 1 or 4 of the Sequence Listing.

2. The method according to claim 1 , wherein the substance for decreasing of the MEX3B gene is administered together with a carrier for lipofection.

3. The method according to claim 1 , wherein the respiratory or pulmonary disease is severe asthma caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5.

4. The method according to claim 1 , wherein the CRISPR/Cas nuclease is CRISPR/Cas9.